Cochrane v. Badische Anilin & Soda Fabrik

111 U.S. 293, 4 S. Ct. 455, 28 L. Ed. 433, 1884 U.S. LEXIS 1784
CourtSupreme Court of the United States
DecidedApril 14, 1884
Docket282
StatusPublished
Cited by76 cases

This text of 111 U.S. 293 (Cochrane v. Badische Anilin & Soda Fabrik) is published on Counsel Stack Legal Research, covering Supreme Court of the United States primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Cochrane v. Badische Anilin & Soda Fabrik, 111 U.S. 293, 4 S. Ct. 455, 28 L. Ed. 433, 1884 U.S. LEXIS 1784 (1884).

Opinion

Mr. Justice Blatchford

delivered the opinion of the court.

This is a suit in equity, brought in the Circuit Court of the United States for the Southern District of New York, by Badische Anilin and Soda Fabrik, a corporation organized under the laws-of the Grand Duchy of Baden, in the Empire of Germany, against th'e appellants, for the infringement of reissued letters patent No. 4,321, granted to Charles Graebe, of Frankfort-on-the-Main, and Charles Liebermann, of Berlin, Prussia, April 4th, 1871, for an “improvement in dyes 'or coloring matter from anthracine.” The original patent, No. 95,4.65, was granted to the same persons, October 5th, 1869, for an “ improved process of preparing alizarine.” It was reissued on two separate amended specifications, Division A and Division B. No. 4,321 is Division B.

The following is the text of the specifications of No. 4,321 and No. 95,465. Beading in it Avhat is outside of braclcéts, and what is inside of the brackets, omitting what is in italics, gives the specification of' No. 4,321. Beading what is outside of brackets, including what is in italics, omitting what is inside of brackets, gives the specification of the original patent:

“ Be it known, that we, Charles Graebe, of Frankfort-on-the-Main, and Charles Liebermann, of Berlin, in the Kingdom of Prussia, have invented a [new and useful improvement in the manufacture of alizarine ;] process for preparing alizarine from anthracine / and wo do hereby declare the following to be a full, clear and exact deséription thereof, which will enable those skilled in the art to .make and use the same. We first change‘theanthra-cine into anthrakinon (oxanthracine), a substance known to [the] chemists by the investigations of Anderson. For this purpose we take one part, by weight, of anthracine, -two and half parts, by weight, of bichromate of [potash,] potassa, and ten or fifteen parts, .by weight, of concentrated acetic acid, and we heat these substances together in a vessel, either of glass or clay, to about 100? centigrade to 120° centigrade, till nearly all of the bichro *295 mate of [potasK] potassa is dissolved and the liquid has acquired a deep green color. We then recover the acetic acid not consumed in the reaction by distillation, and treat the residuum with water to remove the chromic acetate. From the insoluble mass we obtain the anthrakinon in a pure state by distilling the whole from a-' retort of glass of iron. In the place of the acetic acid,- sulphuric acid, diluted with one or two parts of water, may be employed. Instead of the method just described, we also employ the following one: We heat the anthracine .in a vessel of glass or of clay, with ten parts of concentrated acetic acid, to about 100° centigrade, or a little higher, and we add nitric acid of about 1.3 specific gravity, in small portions, till the violent re- ■ action ceases. After distillation of the acetic acid we purify the residuum, as before. We then convert the anthrakinon, prepared by one of the methods described, into bibromanthrakinon. For this purpose we take three parts of anthrakinon, five parts of bromine, and we heat these substances for ten or twelve hours, or until nearly the whole of the bromine has disappeared, to a temperature, by preference, of about 100° centigrade, in a suitable close vessel, either of glass or enameled or glazed iron, which is capable* of sustaining the pressure [which is] generated by the reaction. The apparatus is then allowed to cool. It is opened in order to permit the escape of [bromic] hydrobromic acid, which can be recovered by absorption either in water or in an alkaline solution. We purify the bibromanthrakinon remaining in the vessel, as a. solid substance, by crystallization from benzole. Instead of the method above described for preparing bibromanthrakinon, we also employ the following : We convert first the anthracine, into a bromine derivative, into the tetrabrománthracine, known to chemists by the investigations of Anderson. We take one part of this tetrabromanthracine, and we heat it in a retort of glass or clay with about five parts of nitric acid-of about 1.3 specific gravity to 100° centigrade, as long as vapors of bromine are evolved. We distil off the greater portion of the nitric acid, wash the residuum with water, and purify it by crystallization from benzole. We .thus receive the bibromanthrakinon as before, in the form of a yellow, solid mass. We then convert the bibromanthrakinon into alizarine. For this purpose we take one part of -bibromanthrakinon, two to three parts of caustic potash or soda, and so much water as is necessary to dissolve the alkali, and ■ *296 we heat the whole in an open vessel of glass, glazed or enameled iron, or silver, to about 180° to 260° centigrade for one hour, or [till]' until the mass has acquired a deep blue color. We then dissolve it in water and filter the violet solution, from which we precipitate the alizarine by an inorganic or organic acid. We collect the yellow flocks of alizarine thus .obtained on a filter and wash them with water. By these methods we receive the alizarine in a form in which it can be employed in the same manner as the different preparations from madder. In the place of bromine, chlorine [also] may also be employed, but not so conveniently, as the reactions above described are more difficult to accomplish with chlorine than with bromine. Having thus described the nature of our invention and the manner of performing and carrying out the same, we would have it understood that we do not confine ourselves to the exact details hereinbefore given." ■

The claim of No. 4,321 is as follows: “Artificial alizarine, produced from anthracine or its derivatives by either of the methods herein described, or by any other method which will produce a like result.” The claim of the original patent was in these words : “ The within described process for the production of alizarine, by first preparing bibromanthrakinon or bichloranthrakinon, and then converting these substances into alizarine, substantially as above set forth.”

The bill of complaint alleges that No. 4,321 was issued “for a distinct and separate part of the same invention, on a corrected specification,” on the surrender of No. 95,465 ; and No. 4,321 states, on its face, that, on such surrender1, new letters were ordered to issue “ on two separate amended specifications.” But Division A, No. 4,320, is not in the record before us. The bill alleges the infringement to have been committed by making, selling, or using the invention or dyes containing it. The answer denies the manufacture of alizarine, but avers that the defendants have sold in the United States alizarine lawfully made in Germany, and imported as an article of commerce, which was not made by the process described in No. 4,321, or any process 'Substantially the same, but was made according to processes which were invented subsequently to the date of No. ■95,465, and are the subject of different and independent letters *297 patent.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Biogen 755 Patent Litig.
335 F. Supp. 3d 688 (D. New Jersey, 2018)
The Medicines Company v. Mylan, Inc.
853 F.3d 1296 (Federal Circuit, 2017)
Amgen Inc. v. F. Hoffmann-La Roche Ltd.
580 F.3d 1340 (Federal Circuit, 2009)
Abbott Laboratories v. Sandoz, Inc.
566 F.3d 1282 (Federal Circuit, 2009)
Aktiebolag v. Andrx Pharmaceuticals, Inc.
483 F.3d 1364 (Federal Circuit, 2007)
Smithkline Beecham Corp. v. Apotex [Corrected Date]
439 F.3d 1312 (Federal Circuit, 2006)
Tropix, Inc. v. Lumigen, Inc.
825 F. Supp. 7 (D. Massachusetts, 1993)
In re Brown
459 F.2d 531 (Customs and Patent Appeals, 1972)
Tri-Wall Containers, Inc. v. United States
408 F.2d 748 (Court of Claims, 1969)
Thomson Industries, Inc. v. Nippon Thompson Co.
298 F. Supp. 466 (E.D. New York, 1968)
Merck & Co. v. Chase Chemical Company
273 F. Supp. 68 (D. New Jersey, 1967)
George B. Spero v. Howard J. Ringold and George Rosenkranz
377 F.2d 652 (Customs and Patent Appeals, 1967)
Christensen Diamond Products Co. v. United States
54 Cust. Ct. 221 (U.S. Customs Court, 1965)

Cite This Page — Counsel Stack

Bluebook (online)
111 U.S. 293, 4 S. Ct. 455, 28 L. Ed. 433, 1884 U.S. LEXIS 1784, Counsel Stack Legal Research, https://law.counselstack.com/opinion/cochrane-v-badische-anilin-soda-fabrik-scotus-1884.